Aktiesnakken — Juni 2022
-
Det samme i Norge.
-
Ned kl. 9,40 og derefter op.
-
Ditto i Sverige på minuttet?
-
mystisk - måske noget futop relateret
-
hvis ikke ham med den fede finger ha rlavet en 2ér:)
-
Opdatering på de mest shortede danske aktier
https://www.proinvestor.com/boards/104084 -
Aktier/middag: Mærsk ramt af Biden lov mens C25 stiger efter hård uge
https://www.proinvestor.com/investornyt/839219/aktier-middag-maersk-ramt-af-biden-lov-mens-c25-stiger-efter-hard-uge -
USA/tendens: Udsigt til positiv start efter uge i renteløftenes tegn
https://www.proinvestor.com/investornyt/839288/usa-tendens-udsigt-til-positiv-start-efter-uge-i-renteloftenes-tegn -
SAS er den mest shortede aktie i Norden
https://www.proinvestor.com/investornyt/839307/sas-er-den-mest-shortede-aktie-i-norden -
USA/åbning: Lille aktierevanche fra start - men pres på Adobe
https://www.proinvestor.com/investornyt/839352/usa-abning-lille-aktierevanche-fra-start-men-pres-pa-adobe -
Vi kan håndtere enhver udfordring lover Putin i trodsig tale https://www.proinvestor.com/investornyt/839405/vi-kan-handtere-enhver-udfordring-lover-putin-i-trodsig-tale
-
Fredagens aktier: C25 gik på weekend med plus efter svær uge https://www.proinvestor.com/investornyt/839457/fredagens-aktier-c25-gik-pa-weekend-med-plus-efter-svaer-uge
-
USA/lukning: Teknologi sluttede volatil uge af i festhumør https://www.proinvestor.com/investornyt/839652/usa-lukning-teknologi-sluttede-volatil-uge-af-i-festhumor
-
God morgen.
-
Nasdaq Market Sell-off: Should You Buy Stocks Right Now? https://www.proinvestor.com/investornyt/839737/nasdaq-market-sell-off-should-you-buy-stocks-right-now
-
Stock Market Drop: 3 Cheap Healthcare Stocks to Buy Right Now https://www.proinvestor.com/investornyt/839747/stock-market-drop-3-cheap-healthcare-stocks-to-buy-right-now
-
Steve Bryant, the head of global business development at Genmab A/S, compares the current environment to the market wipeouts of 2000 and 2008, with a handful of key differences. There is – for now – enough extra cash in the hands of large drugmakers who can drive deals, as well as with venture firms that raised funds and can continue to invest.
-
“We’re seeing a lot of companies come forth with assets that they can’t finance,” Bryant said. It’s extremely difficult, he said, especially for smaller companies that may have promising science but haven’t proven the work through more advanced research.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind